3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Carcinoma, Non-Small-Cell Lung
7
Small Cell Lung Carcinoma
3
Squamous Cell Carcinoma of Head and Neck
2
Lymphoma, Non-Hodgkin
2
Lymphoma, B-Cell
2
Esophageal Neoplasms
2
Carcinoma, Hepatocellular
2
Uterine Cervical Neoplasms
1
Urothelial Cancer
1
Urinary Bladder Neoplasms
1
Triple Negative Breast Neoplasms
1
Stomach Neoplasms
1
Solid Tumors
1
Rectal Neoplasms
1
Pancreatic Adenocarcinoma
1
PD-L1-selected Solid Tumors
1
Neoplasms
1
Neoplasm Metastasis
1
Multiple Myeloma
1
Melanoma
1
Lymphoma, Follicular
1
Esophageal Squamous Cell Carcinoma
1
Colorectal Neoplasms
1
Carcinoma, Transitional Cell
1
Carcinoma, Renal Cell
1
Advanced Unresectable or Metastatic Solid Malignancy
1
Advanced Liver Cancers
1
Interventions
Paclitaxel
18
pembrolizumab
16
Cisplatin
16
Fluorouracil
15
Irinotecan
13
tislelizumab
9
Oxaliplatin
8
Nivolumab
8
Docetaxel
8
Leucovorin
6
Capecitabine
5
spartalizumab
4
Levoleucovorin
4
Carboplatin
4
lenvatinib
3
durvalumab
3
Radiotherapy
3
Drug Therapy
3
toripalimab
2
sintilimab
2
regorafenib
2
elgemtumab
2
atezolizumab
2
Itraconazole
2
Injections
2
Gemcitabine
2
Bevacizumab
2
130-nm albumin-bound paclitaxel
2
tremelimumab
1
sitravatinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Esophageal Squamous Cell Carcinoma
×
Tiragolumab
×
Clear all
NCT04543617
2026-04-17
SKYSCRAPER-07
Hoffmann-La Roche
Phase 3
Active not recruiting
760 enrolled